Legislation Quick Search
09/25/2021 12:14 AM
Pennsylvania House of Representatives
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=H&SPick=20190&cosponId=27606
Share:
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


House of Representatives
Session of 2019 - 2020 Regular Session

MEMORANDUM

Posted: January 10, 2019 11:09 AM
From: Representative Clint Owlett
To: All House members
Subject: Carfentanil on the list of Schedule II Controlled Substances - Former HB 127
 
In the near future, I plan to re-introduce legislation (Former HB 127 of 2017-18 Session) that will place the drug, Carfentanil, on the list of Schedule II controlled substances which would severely restrict its availability and make it illegal to possess or distribute without a license or a prescription.

Carfentanil is one of the most potent opioids in existence. It is 10,000 times stronger than morphine and 100 times more powerful than fentanyl. It is commonly used as a tranquilizer for large animals, such as elephants. Carfentanil can slow breathing significantly. It is unsafe for human use, and even a very small dose can be lethal.

Recently, there have been instances where the drug has been added to other opioids like heroin to boost its effect, a cocktail that has resulted in several deaths.

The PA Secretary of Health has taken steps to place Carfentanil on the Schedule II list as a temporary measure under the emergency authority created by the passage of Act 37 of 2016. Though the temporary listing will hold the line on this dangerous drug for the time being, a permanent listing is necessary given it’s lethality if consumed by humans.

I invite you to co-sponsor this legislation.

Previous Co-sponsors: DRISCOLL, PICKETT, JAMES, R. BROWN, READSHAW, GAINEY, KNOWLES, MURT, STAATS, MILLARD, LONGIETTI, HELM, ZIMMERMAN, HEFFLEY and PASHINSKI



Introduced as HB616